As many already know, Pirola, or BA.2.86, is the latest Omicron strain that just appeared this summer, sparking concern among medical experts because it has 34 more mutations, which could make it easier to evade vaccines. Pirola has so far been detected in 15 countries worldwide, according to the Covid variant tracker GISAID, including Denmark, France, USA, Sweden, Thailand, Israel, Spain, Canada, Portugal, Australia, Germany, South Korea and Japan. Pfizer (PFE) and Moderna (MRNA) have already reported their emergency preparations to introduce the specific vaccine boosters. This, quite unexpectedly, means the downplayed lately world healthcare sector might be a big name in most investors’ portfolios again.

Invesco Pharmaceuticals ETF (PJP) is a passively managed exchange-traded fund launched on June 23, 2005 providing broad exposure to the healthcare pharmaceutical sector of the stock market and mirroring The Dynamic Pharmaceuticals Inteldex Index.

The Dynamic Pharmaceuticals Inteldex Index consists of stocks of greater U.S. pharmaceutical companies. It aims to achieve capital appreciation through a comprehensive evaluation of companies based on a variety of investment criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.

While passively managed ETFs are great tools for long-term investors, they are also a popular choice among institutional and retail investors. The fund is sponsored by Invesco. It has amassed over $271.03 million in assets, making it one of the average-sized ETFs that attempts to match the performance of the healthcare pharmaceutical sector of the stock market. PJP is designed to match the performance of the dynamic Pharmaceutical Inteldex Index (before fees and expenses).